Ginger and non-alcoholic fatty liver disease (NAFLD/NASH): reducing liver fat and inflammation

Direct Answer: Ginger is one of the best-documented nutraceuticals against ginger-related liver-detox-enzymes-hepatiques">NAFLD (ginger non-alcoholic fatty liver): AMPK activation in hepatocytes (inhibition of SREBP-1c → less de novo lipogenesis → less hepatic fat); inhibition of hepatic NF-κB (less TNF-α, IL-6, MCP-1 → slowed NASH progression); Nrf2 activation (hepatocyte protection against cortisol-naturel">ginger oxidative stress); and PPAR-α receptor activation (accelerated hepatic fatty acid β-oxidation). RCT 2016: -23% hepatic fat (MRI) and -18% ALT after 12 weeks.

NAFLD in Belgium: the fatty liver of the modern era

Non-alcoholic fatty liver disease (NAFLD) affects 25–30% of Belgian adults, and the inflammatory form (NASH — Non-Alcoholic SteatoHepatitis) affects 3–5%. NASH can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Causes: hyperinsulinemia (ginger insulin resistance), high-calorie/high-fat diet, dysfunctional microbiome. Pathological mechanism: hepatic de novo lipogenesis → accumulation of triglycerides → mitochondrial oxidative stress → hepatocyte necroptosis → anti-inflammatory-science-utilisation">turmeric-poivre-noir-douleur-chronique">natural anti-inflammatory → fibrosis.

Mechanisms of ginger on the liver

1. AMPK → SREBP-1c inhibition → less lipogenesis

SREBP-1c (Sterol Regulatory Element-Binding Protein 1c) is the central transcription factor for hepatic de novo lipogenesis. AMPK, activated by ginger, phosphorylates and inhibits SREBP-1c → less expression of lipogenic enzymes (FAS, ACC, SCD1) → less triglycerides synthesized → reduction of hepatic fat. This is the same mechanism as metformin (an antidiabetic drug used in NAFLD).

2. PPAR-α → accelerated β-oxidation

PPAR-α is the central regulator of fatty acid β-oxidation in hepatic mitochondria. Ginger activates PPAR-α → induction of CPT1 (fatty acid transport into the mitochondrion) → accelerated burning of hepatic fats → reduced intrahepatic triglycerides.

3. NF-κB → hepatic anti-inflammation (NASH)

The NAFLD→NASH transition is mediated by NF-κB in Kupffer cells (hepatic macrophages): TNF-α, IL-6, MCP-1 → activation of stellate cells (HSC) → fibrogenesis. 6-gingerol inhibits NF-κB in Kupffer cells → fewer pro-fibrotic cytokines → slowed NASH→fibrosis progression.

4. Nrf2 → hepatocyte protection

Mitochondrial oxidative stress is the driver of NAFLD progression. Nrf2, activated by ginger, induces the production of SOD, catalase, glutathione peroxidase in hepatocytes → neutralization of mitochondrial ROS → less hepatocyte death.

Clinical results

NAFLD Marker Before ginger After 12 weeks Reduction
Hepatic fat (MRI) 100% 77% -23%
ALT (alanine aminotransferase) ~65 IU/L ~53 IU/L -18%
AST ~55 IU/L ~46 IU/L -16%
Insulin resistance (HOMA-IR) ~4.2 ~3.3 -21%
FAQ — Ginger and NAFLD/NASH

Interactions with metformin (treatment for ginger diabetes and NAFLD)?
Complementary effects (both activate AMPK). No documented negative interaction. Potentially synergistic association for NAFLD associated with diabetes.

Can ginger reverse hepatic fibrosis?
Unlikely on its own. In the mild to moderate fibrosis stage (F1–F2), progression can be slowed. In advanced fibrosis (F3–F4/cirrhosis), specialized hepatology is essential.

Also effective for alcoholic steatosis?
Similar mechanisms (oxidative stress, hepatic NF-κB), so potentially useful, but abstaining from alcohol remains the absolute priority.

🌿 INTI — Belgian Ginger for a less fatty liver
AMPK, PPAR-α, NF-κB, Nrf2 — a proven multi-target action on NAFLD.
→ Order on inti-drink.com

Related articles

To learn more, also read:

Back to blog